Hi A,
Andreas' response is correct. Trying to get interactive review from the lead reviewer is the most efficient method, but only works if the reviewer buys in and the questions are relatively simple.
If you are questioning feedback from the original Q-sub, a "Submission Issue" meeting request might be the best method. The guidance states that reviewers are supposed to schedule a meeting within 21 days of the submission getting stamped into the FDA. I've seen inconsistent responses from FDA to these requests; however, I would say it's worth a shot if you feel that it meets the qualifications.
Page 23 on the linked guidance -
https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM311176.pdfBest,
------------------------------
Michael Nilo
Network Regulatory Partners
Portland OR
United States
------------------------------
Original Message:
Sent: 29-Aug-2017 12:21
From: Anonymous Member
Subject: Pre-Sub Meeting Supplement FDA Feedback response timing
This message was posted by a user wishing to remain anonymous
Hi Everyone,
I was wondering what experience fellow RA's have had regarding the Pre-Sub Meeting Submission process for a PMA (or even a 510k). There is an option to submit follow-up discussions on the Pre-SUB Meeting as a Supplement; however, the guidance document does not state the length of time for a Pre-Sub Supplement to be scheduled or review by FDA. I was wondering if it was 30 days since IDE Supplements are typically reviewed in 30 days; I did not want to assume the same for Pre-Sub Supplements or does FDA response time vary based on the content of the Supplement?
Would someone please be able to discuss their experience the length of time a follow-up question response/teleconference would be scheduled for a Pre-Sub Supplement. Has the experience been based on the complexity of the followup question, (e.g review data (longer) or review testing protocol (30days)?
Looking forward for your feedback so I may plan timelines with my team.
Thank you in advance.